AI can turn complex protocols into first-pass budget inputs, letting sponsors start budgeting sooner while budget builders shift from data entry to review.
|Articles|June 15, 2015
Comprehend Systems Launches ClinOps Solution
Comprehend Systems, a clinical software solutions provider, announced the launch of Continuous Quality for ClinOps.
Advertisement
Comprehend Systems, a clinical software solutions provider, announced the launch of Continuous Quality for ClinOps, a solution that enables clinical operations to unify and analyze its data and automates alerts and collaboration across executives, teams and contract research organizations (CROs).
The solution automates the continuous quality lifecycle, features include:
- Analytics and Visualizations inform your decision-making and collaboration processes on site and operational performance, safety, efficacy and compliance
- Filtering enables end users to remove redundant or unwanted data from the info stream to facilitate exploration and cohort analysis
- Click-through enables the user to broaden or narrow their exploration from portfolio views down to granular study data even with unique data models across studies
- Forecasts for key indicators that predict future outcomes based on historic facts
- Cross Study Benchmarking uses current similar and past trials to inform decisions on current trials
- Monitoring system tracks trends and allows user-driven thresholds to raise events in the system. Early warnings enable ClinOps leaders to take preventative action
- Collaboration provides decentralized users with simultaneous views of analytics and ability to create data-driven tasks and workflows
- Alerts and Notifications of events can be in app or email or both
- Audit trails allows full auditability of system state from any point in time, including user activity for compliance and report configuration for decision history
Advertisement
Related to this article
Trialbee CEO Matt Walz explores the current impact of AI in delivering practical gains in clinical development and reflects on its future potential, where enrollment predictability may be the biggest prize of all.
In this video interview, Carole Berini, PhD, of Ontada, explains how validated proxies for variables like ECOG performance status can recover not just sample size but the representativeness of hard-to-reach patient populations in real-world oncology studies.
A biomarker test now decides who enters a precision medicine trial, yet results often go unused and assays are not ready when screening opens.
In today's ACT Brief, we examine proportionate analysis frequency in RBQM, how to build trust into real-world evidence foundations for cancer trials, and how rare disease developers monetize regulatory success.
Real-time RBQM requires proportionate analysis frequency matched to data arrival and issue criticality, not continuous reanalysis, because signal churn from over-frequent runs creates alert fatigue and operational noise that obscures meaningful deterioration.
In this video interview, Saamir Pasha and Carole Berini, PhD, of Ontada, explain how building trust into the data foundation—through source lineage, standardization, and reconciliation—is what makes reliable real-world evidence generation in oncology possible.
In today's ACT Brief, we examine how AI surfaces design flaws before enrollment, why site training readiness depends on learning science, and the priorities defining next-generation weight-loss therapies.
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
Real-Time Data, Right-Time Decisions: Rethinking Analysis Frequency in RBQM
2
AI and Patient Recruitment: Can Predictive Promise Drive True Transformation?
3
FDA Releases Transparency Roadmap Outlining Disclosure Priorities Across Drug Development and Regulatory Review
4
What It Takes to Harmonize AI Across Fragmented Oncology Health Systems
5